Anthony O. Pergola Partner

New York
T 212.204.8689 | F 973.597.2445

Anthony O. Pergola is the Vice Chair and a founder of Lowenstein Sandler's Tech Group.

Chambers USA: America's Leading Lawyers for Business called Anthony a "deal-machine" and touted his "attention to detail, management and negotiation skills and ability to solve technical problems," which make deals "his strong suit" (2007) and singled him out as being "practical, efficient and meticulous" (2008). Anthony is also listed among The Best Lawyers in America. Anthony's clients create, finance and bring to market new technologies in the IT/software, communications, financial services, and life sciences/biotech industries, among others. He assists emerging, growth, later-stage technology businesses, and the venture funds that finance them, in venture capital investments. As those companies mature, he helps them to effect critical liquidity events -- whether through the sale of the company or IPO. Anthony also represents financial and strategic buyers in purchasing venture-backed technology businesses; he has closed dozens of M&A transactions. Anthony also represents publicly-held companies in the life sciences and technology sectors. Anthony has written and lectured extensively about business and legal topics impacting public and venture-backed technology and life sciences businesses, ranging from venture issues to corporate governance and Sarbanes-Oxley.

Anthony is an active angel investor and is a founding member of Grape Arbor, a group of angel investors that has consummated more than a dozen angel investments into technology or financial services companies in the last two years. Anthony is also a member of the working group that authored and revised the National Venture Capital Association's Model Legal Documents.

Anthony is a founding board member and currently on the Executive Committee of VentureCrushAV, a network of angel investors and 30 venture funds dedicated to assisting early-stage ventures in the NY and Mid-Atlantic region. Anthony sang a cappella with Harvard Law's "Scales of Justice" and aced the advanced placement test in Pascal computer programming in High School. He's working on being a bit cooler these days, but not doing a great job of it!


President Signs JOBS Act
Corporate Finance Client Alert, April 5, 2012
Marita Makinen, Anthony Pergola, John D. Hogoboom
Term Sheets Play Pivotal Role in Financing for Tech Ventures
Finance & Accounting View, Summer 2007
Anthony Pergola
The Price of Silence
The Deal, March 30, 2006
Steven Hecht, Anthony Pergola
View More...

Press Mentions

Lowenstein Sandler’s Tech Group is representing Yodle, a leader in cloud- based marketing solutions, in its pending acquisition by Group, Inc. provide Internet services and online marketing solutions for small businesses. The merger is anticipated to reinforce’s position as a leading national provider in value-added digital marketing solutions to small businesses. Acquiring Yodle enables to add complementary vertical market solutions, franchise specific products and cloud based office automation business applications for their existing and new clients. The transaction is anticipated to close by the end of the first quarter 2016. The Lowenstein deal team was led by Anthony O. Pergola, Edward M. ZimmermanAlex Leibowitz and Rob Lynn. , February 11, 2016
Lowenstein Sandler represented Celldex Therapeutics, Inc. in connection with its $200.1 million public offering of common stock underwritten by Jefferies LLC and Leerink Partners LLC as joint book-running managers, Guggenheim Securities, LLC acting as lead manager, and Oppenheimer, Brean Capital, Cantor Fitzgerald and ROTH Capital Partners as co-managers. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Celldex’s pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. The Lowenstein team included Anthony O. Pergola, Alan Wovsaniker, Michael J. Lerner, Meredith Prithviraj, Robert J. Paradiso, Michael Amalfe and Eugene Cheval. , March 3, 2015
Lowenstein Sandler represented Vitals in connection with its acquisition of Compass Healthcare Advisers. According to the companies, Vitals is a leader in providing online transparency tools and data, helping consumers make informed decisions about their medical care while Compass Healthcare Advisers extends this capability, by aligning the economic interests of patients & their employers. Financial terms of the transaction were not disclosed. The Lowenstein attorneys who worked on the transaction are Anthony O. Pergola, Eric J. Weiner and Jocqueline M. Kaup. , October 29, 2014
Lowenstein Sandler is representing SilverSky, the leading independent provider of cloud-based security software and managed services, in its acquisition by BAE Systems plc, a British multinational defense, security and aerospace company headquartered in London. The transaction was announced on October 21, 2014. The Lowenstein team includes Anthony O. Pergola, David B. Haber, Brian A. Silikovitz, Andrew E. Graw, Alex D. Leibowitz, Jamie Kapalko, and Darren S. Goodman. , October 21, 2014
Lowenstein Sandler represented Celldex Therapeutics, Inc. in a clinical trial collaboration agreement with Bristol-Myers Squibb to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol’s investigational PD-1 immune checkpoint inhibitor, in combination with Celldex’s targeting investigational antibody varlilumab. Nivolumab and varlilumab are part of a new class of cancer treatment drugs known as immunotherapies. The Lowenstein deal team was led by Michael J. LernerAnthony O. Pergola and Nicholas G. Mehler. , May 15, 2014
Lowenstein Sandler represented Celldex Therapeutics in its $191 million (gross) underwritten public offering of common stock, which closed on December 10, 2013. Jefferies LLC and Leerink Swann LLC acted as joint book-running managers of the offering. Guggenheim Securities, Oppenheimer & Co. Inc., Wedbush PacGrow Life Sciences, Brean Capital, LLC, Cantor Fitzgerald & Co. and ROTH Capital Partners acted as co-managers of the offering. The Lowenstein Sandler team was led by Anthony O. PergolaMichael J. Lerner and Alan Wovsaniker, with Meredith Prithviraj, Jared Heady and Robert Paradiso. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Celldex’s pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body’s immune response. , December 10, 2013
In the Wall Street Journal, Lowenstein Sandler is highlighted as the legal advisor to Liazon Corporation in the $215 million acquisition by Towers Watson. Anthony O. Pergola led the team at Lowenstein Sandler which assisted Liazon in that transaction. , Wall Street Journal , November 22, 2013
Anthony O. Pergola comments on the percentage growth of pharmaceutical and other health care-related venture funding activity in New Jersey, which, along with early-stage investing, stood out as bright spots in an otherwise challenging fourth quarter. , NJBiz , February 2, 2009
Anthony O. Pergola spotlighted as the legal expert in a feature on the role term sheets play in financing high-tech, start-up ventures. , Finance & Accounting View , Summer 2007
Anthony O. Pergola discusses the challenges presented by Sarbanes-Oxley to the venture capital community, in an article focusing on the testimony before a Congressional committee hearing of Mark Heesen, President of the National Venture Capital Association. , Alternative Universe , June 11, 2007
Anthony O. Pergola comments on climbing Sarbanes-Oxley compliance costs and the role technology is playing to keep them at bay , Vertical Systems Reseller , June 2005
Anthony O. Pergola comments on Nasdaq's move to delist Colorado-based technology company Advanced Energy Industries for "Disclaimed Opinion." , Compliance Week , May 17, 2005
Anthony O. Pergola is quoted on Sarbanes-Oxley compliance costs. , Investment Dealers' Digest , May 2, 2005

Related Areas

Capital Markets & Securities
Life Sciences
Mergers & Acquisitions
The Tech Group
Venture Capital, Angel Investing, and M&A


Harvard Law School ( J.D. , 1995 ) , cum laude
Saint Peter's University ( B.A. , 1992 ) , summa cum laude
  • Salutatorian, Student Body President, Alpha Sigma Nu (National Jesuit Honors Society)

Bar Admissions

New York
New Jersey
District of Columbia


  • Member, Board of Trustees of Saint Peter's University
  • Co-Chair/Founding Board Member, VentureCrushAV
  • NVCA Model Legal Documents Project
  • Co-Founding Member, Grape Arbor
  • Trustee, Harvard Law School Association of New Jersey (2007)
  • Metropolitan Corporate Counsel Law Firm Advisory Committee